SANAI HEALTH GP (01889) Reports Interim Results with Attributable Loss of HK$10.861 Million, Turning from Profit to Loss Year-over-Year

Stock News

Aug 28, 2025

SANAI HEALTH GP (01889) announced its interim results for the six months ended June 30, 2025. The group recorded revenue of HK$47.222 million, representing a year-over-year increase of 28.57%. The company reported a loss attributable to owners of HK$10.861 million, compared to a profit of HK$9.971 million in the same period last year. Loss per share was 7.1 cents. According to the announcement, the revenue increase was primarily attributed to higher revenue from pharmaceutical product sales by Beijing Hanyang during the period.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1152751188"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1152751188\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1152751188?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-28 21:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152751188","market":"sh","top_or_hot":-1,"title":"SANAI HEALTH GP (01889) Reports Interim Results with Attributable Loss of HK$10.861 Million, Turning from Profit to Loss Year-over-Year","media":"Stock News","content":"<p>SANAI HEALTH GP (01889) announced its interim results for the six months ended June 30, 2025. The group recorded revenue of HK$47.222 million, representing a year-over-year increase of 28.57%. The company reported a loss attributable to owners of HK$10.861 million, compared to a profit of HK$9.971 million in the same period last year. Loss per share was 7.1 cents. According to the announcement, the revenue increase was primarily attributed to higher revenue from pharmaceutical product sales by Beijing Hanyang during the period.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SANAI HEALTH GP (01889) Reports Interim Results with Attributable Loss of HK$10.861 Million, Turning from Profit to Loss Year-over-Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSANAI HEALTH GP (01889) Reports Interim Results with Attributable Loss of HK$10.861 Million, Turning from Profit to Loss Year-over-Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-08-28 21:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SANAI HEALTH GP (01889) announced its interim results for the six months ended June 30, 2025. The group recorded revenue of HK$47.222 million, representing a year-over-year increase of 28.57%. The company reported a loss attributable to owners of HK$10.861 million, compared to a profit of HK$9.971 million in the same period last year. Loss per share was 7.1 cents. According to the announcement, the revenue increase was primarily attributed to higher revenue from pharmaceutical product sales by Beijing Hanyang during the period.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01889","symbol_name":"三爱健康集团","start_time":0,"source_url":"","article_id":"1152751188","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152751188","pubTimestamp":1756388666,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SANAI HEALTH GP (01889) announced its interim results for the six months ended June 30, 2025. The group recorded revenue of HK$47.222 million, representing a year-over-year increase of 28.57%. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01889":"三爱健康集团","BK1191":"制药"},"translate_title":"三爱健康GP(01889)公布中期业绩应占亏损1086.1万港元同比由盈转亏","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01889":1},"content_text":"SANAI HEALTH GP (01889) announced its interim results for the six months ended June 30, 2025. The group recorded revenue of HK$47.222 million, representing a year-over-year increase of 28.57%. The company reported a loss attributable to owners of HK$10.861 million, compared to a profit of HK$9.971 million in the same period last year. Loss per share was 7.1 cents. According to the announcement, the revenue increase was primarily attributed to higher revenue from pharmaceutical product sales by Beijing Hanyang during the period.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}